Indian Market Live Update at 10:00 AM IST

Nifty Trades Flat as RBI Minutes Signal Hawkish Tone; Infosys Secures Major Deal

Direct answer

Indian markets are trading cautiously this morning, with the Nifty 50 largely flat, as investors digest the hawkish minutes from the Reserve Bank of India's latest Monetary Policy Committee meeting, released earlier today. The minutes revealed stronger-than-expected concerns over persistent inflation among some members, potentially signaling a prolonged high-interest rate regime. Meanwhile, the IT sector received a boost after Infosys announced a significant multi-year deal with a global client, providing some positive momentum.

Key highlights

• RBI MPC Minutes: Released this morning, indicating a more hawkish stance from some members due to inflation concerns, impacting bond yields.
• Infosys Deal: Announced a new multi-year, multi-million dollar deal with a European automotive major, bolstering IT sector sentiment.
• Crude Oil Prices: Brent crude surged past $95 per barrel overnight amidst fresh geopolitical tensions, raising concerns about import bills and inflation.
• Mid-Cap Pharma: Laurus Labs shares gained over 3% after receiving USFDA approval for its generic drug, boosting the company's growth prospects.
• Nifty 50: Trading marginally lower by 0.1% at 23,850 points as of 09:55 AM IST, reflecting mixed market sentiment.

RBI MPC Minutes Signal Prolonged Hawkish Stance Amid Inflation Concerns

The Reserve Bank of India (RBI) today released the minutes of its latest Monetary Policy Committee (MPC) meeting, held from October 7-9, 2026, which revealed a more hawkish undertone than market participants had anticipated. The minutes, published at 8:30 AM IST, indicated that several MPC members expressed heightened concerns about the persistence of core inflation, despite recent moderation in headline figures. Governor Shaktikanta Das reiterated the committee's commitment to bringing inflation within the target band, emphasizing that the "withdrawal of accommodation" stance remains appropriate.

Specifically, two external members reportedly voted for a 25 basis point rate hike, citing upside risks to inflation from rising global commodity prices and robust domestic demand. This divergence in views, while not leading to an immediate rate change, suggests that the central bank might be less inclined to consider rate cuts in the near future than previously hoped by some sections of the market. The hawkish commentary has led to a slight uptick in benchmark government bond yields, with the 10-year G-sec yield rising by 3 basis points to 7.28% in early trade. Banking stocks, particularly those sensitive to interest rate changes, are trading with a cautious bias. Analysts from a leading brokerage firm noted that the minutes reinforce the "higher for longer" interest rate narrative, which could impact credit growth and corporate earnings in the coming quarters.

Why it matters

The RBI's stance is crucial for the trajectory of interest rates, which directly impacts borrowing costs for businesses and consumers. A prolonged period of high rates could temper economic growth, but is seen as necessary to anchor inflation expectations. The minutes provide forward guidance, influencing investor sentiment across equities, debt, and currency markets.

Infosys Secures Major Multi-Year Deal, Boosts IT Sector Confidence

Infosys, India's second-largest IT services company, announced this morning a significant multi-year, multi-million dollar deal with a prominent European automotive manufacturer. The announcement, made via an exchange filing to the BSE at 9:15 AM IST, stated that Infosys will be the strategic partner for the client's digital transformation journey, focusing on cloud migration, AI-driven solutions, and enterprise application modernization. While the exact financial terms were not disclosed, sources close to the development suggest the deal value could be in the range of $500-700 million over a five-year period.

Following the news, Infosys shares opened higher and are currently trading up by 1.8% at ₹1,685 on the NSE, outperforming the broader Nifty IT index, which is up by 0.9%. This win comes at a crucial time for the Indian IT sector, which has faced headwinds from global macroeconomic uncertainties and cautious client spending. Analysts view this deal as a strong indicator of resilient demand for digital transformation services, particularly in niche areas like AI and cloud. A report from a domestic brokerage highlighted that such large deal wins are vital for maintaining revenue growth momentum and improving order book visibility for IT majors. The positive sentiment from this announcement is also spilling over to other large-cap IT peers, including TCS and Wipro, which are also seeing modest gains.

What to watch next

Investors will be keen to see if other IT companies announce similar large deal wins in the coming weeks, which could signal a broader recovery in client spending. The company's management commentary on the deal's impact on margins and future growth outlook will also be closely watched during upcoming analyst calls.

More stocks and market news

Crude Oil Jumps Above $95, Pressuring OMCs and Inflation Outlook

Brent crude oil prices surged overnight, climbing over 2% to trade above $95 per barrel this morning, following renewed geopolitical tensions in the Middle East and concerns over supply disruptions. This sharp rise in global oil benchmarks is a significant concern for India, a major oil importer. Shares of Indian oil marketing companies (OMCs) like Indian Oil Corporation (IOC), Bharat Petroleum Corporation (BPCL), and Hindustan Petroleum Corporation (HPCL) are trading lower by 1-2% as higher crude prices could squeeze their marketing margins if retail fuel prices are not adjusted commensurately. The elevated crude prices also fuel inflationary pressures, potentially complicating the RBI's monetary policy decisions.

Laurus Labs Gains on USFDA Approval for Generic Drug

Laurus Labs shares are in focus today, trading up by over 3.5% at ₹420 on the NSE, after the company announced receiving final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for a generic drug. The approval, announced in an exchange filing at 9:00 AM IST, is for a widely used anti-retroviral drug, opening up a new market opportunity for the Hyderabad-based pharmaceutical company in the lucrative US market. This development is expected to contribute positively to Laurus Labs' revenue and profitability in the coming quarters, reinforcing its position in the global generics space.

Market context

As of 09:55 AM IST, the Nifty 50 is trading at 23,850, down marginally by 0.1%, while the Sensex is at 79,200, also down by about 0.15%. The Nifty Bank index is showing slight weakness, down 0.2%, reflecting the cautious sentiment post-RBI minutes. India VIX, the volatility index, has risen by 0.8% to 12.80, indicating a minor increase in market apprehension. Global cues are mixed, with Asian markets largely flat to negative, while US futures point to a subdued opening.

Why these stories matter

The RBI MPC minutes are paramount as they dictate the future course of interest rates, directly impacting credit growth, corporate earnings, and overall economic activity. The Infosys deal win is a crucial sentiment booster for the IT sector, a major contributor to India's exports and market capitalization, signaling demand resilience. Rising crude oil prices pose a significant macro risk, threatening to reignite inflation and widen the current account deficit, while specific company approvals like Laurus Labs' USFDA nod highlight execution and growth opportunities within sectors.

What to watch next

• Global Crude Oil Movement: Continued monitoring of geopolitical developments and their impact on oil prices.
• Q2 FY27 Earnings Season: Commencement of the second-quarter earnings season, with initial results from IT and banking majors expected next week.
• FII/DII Flow Data: Daily foreign and domestic institutional investor activity will be crucial for market direction.
• Government Bond Yields: Watch for further movements in G-sec yields post-RBI minutes.

Sources

• Reserve Bank of India
• Moneycontrol: RBI MPC Minutes Highlights
• BSE India: Infosys Exchange Filing
• Reuters: Crude Oil Prices Surge on Geopolitical Tensions
• Business Standard: Laurus Labs USFDA Approval

FAQ

1. What did the RBI MPC minutes reveal today?

The RBI MPC minutes, released today, indicated a more hawkish stance from some members due to persistent inflation concerns, suggesting a potential for prolonged high-interest rates. Two external members reportedly voted for a 25 basis point rate hike.

2. How is the Infosys deal impacting its stock and the IT sector?

Infosys shares are up by 1.8% after the company announced a significant multi-year, multi-million dollar deal with a European automotive client. This has boosted sentiment for the broader IT sector, with the Nifty IT index also seeing gains, as it signals resilient demand for digital transformation services.

3. Why are crude oil prices rising and what is its impact on India?

Brent crude oil prices surged past $95 per barrel due to renewed geopolitical tensions and supply disruption concerns. For India, a major oil importer, this raises worries about increased import bills, potential inflationary pressures, and could negatively impact the margins of oil marketing companies.

4. What is the significance of Laurus Labs' USFDA approval?

Laurus Labs received final USFDA approval for a generic anti-retroviral drug, which is a positive development. This opens up new market opportunities for the company in the lucrative US market and is expected to contribute to its revenue and profitability.

5. What is the current market sentiment in India this morning?

Indian markets are trading cautiously this morning. The Nifty 50 and Sensex are marginally lower, influenced by the hawkish RBI MPC minutes and rising crude oil prices. However, positive news from the IT and Pharma sectors is providing some support.

Disclaimer: This article is for educational purposes only. It does not constitute investment advice. Please consult a SEBI-registered financial advisor before making investment decisions.